Pancreatic cancer is one of the deadliest cancers because it is usually found late and is difficult to treat. Most patients cannot have surgery, and even those who do often see the cancer return. The tumor is surrounded by a dense, fibrous barrier that blocks drugs from reaching cancer cells and creates an environment that weakens immune responses, making standard chemotherapy and immunotherapy less effective.
Researchers are now exploring hydrogels as a new way to overcome these barriers. Hydrogels are soft, water-rich materials that can be injected directly into or near the tumor. Once in place, they slowly release cancer drugs over time, delivering high doses exactly where they are needed while reducing side effects to the rest of the body. Some hydrogels are designed to respond to the tumor environment, releasing drugs only when they sense conditions like acidity or low oxygen.
Hydrogels are being tested to deliver chemotherapy, boost immune responses, improve radiation therapy, or combine multiple treatments at once. New designs are also tailored to the genetic features of pancreatic cancer, allowing targeted delivery of gene-based therapies. Although most results so far come from animal studies, researchers are working to make hydrogels safe, consistent, and easy to use in clinical settings, with the goal of bringing this technology to patients in the future.